[1] 王蒙蒙,李恩,汪涛,等.冠心病患者胱抑素C及糖化血红蛋白水平与冠脉病变的关系[J].实用医学杂志,2015,31(22):3704-3707. [2] 袁琳,类延娜,李玉子,等.组织蛋白酶K、胱抑素C与冠心病及其危险因素的相关性[J].中国老年学杂志,2015,35(23):6725-6727. [3] Levin A, Lan JH. Cystatin C and cardiovascular disease: Causality, association, and clinical implications of knowing the difference[J].J Am Coll Cardiol,2016, 68(9):946. [4] 赵红丽,李潞,王帅,等.老年冠心病患者胱抑素C、β2微球蛋白水平及临床意义[J].中国老年学杂志,2013,33(21):5262-5264. [5] 何姗姗,王晓燕,赵英帅,等.冠心病患者冠状动脉病变程度与血清胱抑素C及内皮功能相关性分析[J].重庆医学,2017,46(1):64-67,71. [6] Laan SW, Fall T, Soumaré A,et al. Cystatin C and cardiovascular disease: A mendelian randomization study[J].J Am Coll Cardiol,2016, 68(9):934-945. [7] 邵丽川,岑结容,麻春桃,等.血清胱抑素C与老年冠心病冠脉病变程度的相关性研究[J].河北医药,2015,37(12):1825-1827. [8] Lee SH, Youn YN, Choo HC,et al.Cystatin C as a predictive marker of renal dysfunction and mid-term outcomes following off-pump coronary artery bypass grafting[J].Heart,2015, 101(19):1562-1568. [9] 汤益民,朱建华.血清胱抑素C在冠脉介入相关肾功能损害中的应用价值[J].心脑血管病防治,2011,11(3):184-186.
2019, Vol. 36 
